ArticleInfectious diseases and therapy2026
Practical Considerations Shaping Pneumococcal Vaccine Selection: A Multinational Cross-Sectional Survey of Healthcare Professionals.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe pneumococcal vaccine landscape now includes multiple vaccines differing in age indications and serotype compositions. While clinical attributes such as effectiveness, safety, and disease coverage are key considerations, healthcare professionals (HCPs) also confront operational aspects of vaccination, such as managing multiple vaccines across pediatric and adult populations which are less well characterized. This study assessed HCP priorities and practical considerations for pneumococcal vaccine selection and the additional serotype coverage required to justify use of an adult-specific vaccine instead of the same vaccine across children and adults.
methodsThis cross-sectional online survey involved 500 HCPs (physicians, nurses, and pharmacists) from Australia, Canada, France, Mexico, and Taiwan. The perceived importance of pneumococcal vaccination, practical considerations, perceived challenges and benefits of using a single vaccine across age groups versus separate age-specific vaccines, and the serotype coverage difference to justify use of multiple pneumococcal vaccines strategies were assessed.
resultsPneumococcal vaccination was rated as important by 97.6% of HCPs for children and 99.2% for adults. Implementation factors important to HCPs included logistical hurdles while ordering and stocking (94.0%) and minimal storage requirements (84.4%). Use of separate pediatric and adult vaccines was considered to increase refrigeration requirements (90.0% agreeing) and stock handling complexity (89.1%), whereas use of a common vaccine across age groups was perceived to provide cost savings at practice level (85.1%) and health system level (83.4%). HCPs also agreed that a single vaccine would reduce the potential for medical errors (96.3%) and improve inventory management (93.0%). An average difference of 34.7 ± 16.8% in adult-specific invasive pneumococcal disease serotype coverage was perceived by HCPs to justify adding an adult-specific vaccine rather than using a single vaccine across age groups.
conclusionHCPs balance clinical attributes with real-world delivery constraints when selecting pneumococcal vaccines, and favor simpler, single-vaccine strategies across age groups unless separate vaccines offer a clearly substantial coverage advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.